This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects


Grimaldi, Luigi Maria, Zappalà, Giuseppe, Iemolo, Francesco, Castellano, Anna, Ruggieri, Stefano, Bruno, Giuseppe, Paolillo, Andrea


Journal Of Neuroinflammation, Volume: 11, Pages.: 30-30

Year of Publication



Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer’s patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer’s Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.;

Bibtex Citation

@article{Grimaldi_2014, doi = {10.1186/1742-2094-11-30}, url = {}, year = 2014, publisher = {Springer Nature}, volume = {11}, number = {1}, pages = {30}, author = {Luigi Maria Grimaldi and Giuseppe Zappal{`{a}} and Francesco Iemolo and Anna Castellano and Stefano Ruggieri and Giuseppe Bruno and Andrea Paolillo}, title = {A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects}, journal = {Journal of Neuroinflammation} }


adjuvants immunologic, aged, alzheimer disease, analysis of variance, double-blind method, drug therapy, female, humans, interferonbeta, male, mental status schedule, middle aged, neuropsychological tests, pilot projects, retrospective studies, therapeutic use, time factors, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions